Leader Formulas recalled RAPTURE lot 260327-4 nationwide after FDA testing found undeclared DMAA; no related adverse events were reported to the company.

A nationwide recall is underway for one lot of RAPTURE Preworkout after U.S. Food and Drug Administration testing found an undeclared stimulant in the dietary supplement.

Leader Formulas, LLC., of Tomball, Texas, is voluntarily recalling lot 260327-4 of RAPTURE Preworkout because the product was found to contain 1,3-dimethylamylamine, or DMAA, even though DMAA was not disclosed on the product label. FDA posted the company recall announcement on October 7, 2026. [1]

The recall covers three flavors distributed nationwide through retail outlets and online sales between January 29, 2025 and May 25, 2026. [1]

Importantly, the hidden DMAA finding itself is not new. FDA had already issued a public notification on May 5, 2026, after laboratory analysis confirmed undeclared 1,3-DMAA in RAPTURE Preworkout. The new development is the subsequent nationwide voluntary recall of the affected lot. [2]

Which RAPTURE Products Are Recalled?

All recalled products belong to lot 260327-4 and are sold as 450-gram pre-workout dietary supplement powder containers. FDA describes the packaging as round plastic containers with red and black lettering and a rhinoceros-print seal on the top. [1]

The UPCs above reproduce the identifiers as currently listed in FDA's recall notice. [1]

Leader Formulas is notifying distributors and customers and arranging return of recalled products. Consumers who have an affected container should stop using it and return it to the place of purchase for a full refund. [1]

What Changed in October?

FDA did not first discover the hidden stimulant this week.

On May 5, the agency publicly warned consumers not to purchase or use RAPTURE Preworkout after its laboratory testing detected 1,3-DMAA that was not declared on the label. [2]

The October development moves the product from an FDA hidden-ingredient public notification to a formal nationwide voluntary recall of one identified lot.

There is also a noteworthy timeline detail. FDA's May warning is dated May 5, while the October recall notice states that the affected product was distributed through May 25, 2026. The public materials reviewed for this article do not explain that timeline, so no inference should be made about specific shipments or when individual distributors received notice. [1] [2]

What Is DMAA?

DMAA, or 1,3-dimethylamylamine, is a stimulant also known as methylhexanamine.

FDA describes DMAA as an amphetamine derivative that has historically been marketed in products promoted for sports performance and weight loss. The agency says DMAA is not a dietary ingredient, and products marketed as dietary supplements containing DMAA violate U.S. law. [3]

FDA also considers DMAA added to a dietary supplement to be an unsafe food additive and advises consumers not to purchase or use supplements containing it. [3]

That regulatory history makes this recall different from a routine labeling discrepancy: the undeclared substance is itself one that FDA has repeatedly acted to remove from products marketed as dietary supplements.

Why Hidden DMAA Matters Clinically

FDA states that DMAA can constrict blood vessels and raise blood pressure.

Potential cardiovascular effects identified by the agency include shortness of breath, chest tightness, arrhythmias and heart attack. FDA also lists seizures and other neurologic or psychological effects among potential health concerns. [3]

FDA further notes that DMAA may present greater concern when used with other stimulant ingredients such as caffeine. [3]

That does not establish that every person exposed to RAPTURE will develop these effects, nor does the recall provide a DMAA concentration from which individual risk can be calculated.

The toxicology concern is instead one of unrecognized exposure.

A consumer may believe they are taking only the ingredients printed on the pre-workout label while actually being exposed to an additional stimulant capable of altering blood pressure and cardiovascular physiology.

MedicalToxic has documented the same broader diagnostic problem with other adulterated consumer products in FDA Finds Hidden Sildenafil and Tadalafil in Two Sexual-Enhancement Products: the label may not provide the clinician with the patient's full pharmacologic exposure.

No Adverse Events Have Been Reported to the Company

The recall notice states that Leader Formulas had not received reports of adverse events related to the recall at the time of the announcement. [1]

That wording should remain precise.

It does not establish that no exposed consumer has ever experienced symptoms, nor does it provide the number of people who used the affected products.

The notice also does not disclose:

• the concentration of DMAA detected;

• the number of recalled containers distributed;

• the number of consumers exposed; or

• a product-specific incidence of adverse effects.

The recall therefore identifies a confirmed product adulteration problem without quantifying the clinical event rate.

Why This Matters for Poison Centers and Emergency Clinicians

An undeclared stimulant can complicate the assessment of a patient presenting after pre-workout supplement use.

When clinically relevant, exposure history should include the specific product, flavor, lot number, amount used, timing of use and other stimulant exposures, rather than relying only on the ingredient list printed on the container.

This issue extends beyond RAPTURE. MedicalToxic previously highlighted undeclared pharmacologically active substances in supplements in Weekly Safety Pulse: FAERS & Recalls.

The current RAPTURE case is distinct because FDA testing specifically confirmed 1,3-DMAA, and the October action now concerns a defined recalled lot.

This News does not establish a new treatment protocol for stimulant toxicity. Clinical management should be driven by the patient's actual physiology and severity rather than by the recall alone.

What Consumers Should Do

Consumers should check RAPTURE Preworkout containers for lot 260327-4.

If the lot matches, the recall instructs consumers to stop using the product and return it to the place of purchase for a full refund. [1]

People who believe they experienced health problems related to the product should contact a healthcare professional. FDA also directs consumers and healthcare professionals to report suspected adverse reactions through the MedWatch program. [1]

What Is Genuinely New?

The genuinely new event is the nationwide voluntary recall of RAPTURE Preworkout lot 260327-4.

FDA had already publicly confirmed undeclared DMAA in the product in May. [2]

The October notice adds several actionable details:

• a specific affected lot;

• three affected flavors;

• nationwide retail and online distribution;

• instructions to stop using and return affected products; and

• confirmation that the company is conducting the recall with FDA's knowledge. [1]

This makes the recall a legitimate new News event rather than a rewrite of the earlier May laboratory finding.

Limitations and Unknowns

The public recall does not disclose the amount of DMAA present in the product.

It also does not report how many units remain in consumer possession, how many individuals used the affected lot or whether the absence of reports to the company reflects the absence of adverse outcomes.

FDA's established DMAA safety information describes potentially serious cardiovascular and neurologic effects, but those general DMAA hazards should not be converted into a claim that RAPTURE has caused heart attacks, seizures or another specific clinical outcome in users of this recalled lot. [3]

Likewise, risk cannot be quantified from the recall announcement.

Conclusion

The RAPTURE recall represents a confirmed hidden-stimulant problem rather than a speculative safety signal.

FDA laboratory testing established that the product contained undeclared 1,3-DMAA, and Leader Formulas is now recalling lot 260327-4 nationwide. [1] [2]

The recall does not document an outbreak of DMAA poisoning, and the company reports no related adverse-event reports to date.

But the toxicology relevance is clear: consumers may unknowingly receive a stimulant that FDA says can raise blood pressure and cause serious cardiovascular and neurologic effects.

For consumers and clinicians, the most actionable details are straightforward: identify the product and lot, stop use of recalled containers, and do not assume a pre-workout label necessarily reveals every pharmacologically active exposure.

References

1. U.S. Food and Drug Administration. (2026, October 7). Leader Formulas, LLC. Issues Voluntary Nationwide Recall of RAPTURE Preworkout Due to the Presence of 1,3-Dimethylamylamine (DMAA).

2. U.S. Food and Drug Administration. (2026, May 5). RAPTURE Preworkout may be harmful due to hidden ingredient.

3. U.S. Food and Drug Administration. DMAA in Products Marketed as Dietary Supplements.